Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy. (AmInnovation)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-06-01
End date: 2019-11-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong. AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate. AmyPore solution, called “AmyP53” is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases. As a matter of fact, relying upon : - an exclusive license, linked to an international patent owned by the inventors, - recent scientific publications, - and additional recent conclusive tests, AmyP53 is : - easy to test, - easy to produce worldwide, - easy to administer. AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.

Keywords: alzheimer s disease,parkinson s disease,innovative treatment
A Study of the Notion of Ampleness in Model Theory and Tits Buildings (AMPLE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-09-01
End date: 2021-08-31
Duration (months): 24.0
Total project cost (EUR): 212933.76
EU funding (EUR): 212933.76
Participants: 1
Project status: CLOSED

The proposed project AMPLE allocates in the area of mathematical Logic, Model Theory. It aims to develop a full understanding of the notion of ampleness and establish new connections between Model Theory and core mathematics. Model Theory aims to study and classify mathematical structures according to their THEORIES, that is, the class of all first order logic sentences that are true within them. One of the most important conjectures within Model Theory is Zilber's Trichotomy Conjecture, which suggested a classification of so-called strongly minimal structures - the building bricks of large classes of first order structures. Even though having been refuted quickly after its formulation, this conjecture and its counter example by Hrushovski have shaped the research in model theory and ultimately led Hrushovski to his outstanding proofs of the Mordell-Lang Conjecture, originating in the area of Number Theory. The notion of AMPLENESS was developed in order to classify the geometries left out in the Trichotomy Conjecture. Even though studied by many after its introduction, there is a plethora of open questions around this notion, witnessing that a thorough understanding is still missing. Answers to these questions have the potential to reshape the view on the classification of first order structures. The ER managed in her PhD thesis to solve one of the main open problems in this area, by combining tools from the field of TITS BUILDINGS, which was developed to classify simple algebraic groups and groups of Lie type. Together with the project Supervisor, who is a leading expert in the area of ampleness, the ER will establish a full understanding of the notion of ampleness, using its close connections to the theory of Tits Buildings. This project promises new bonds between Model Theory and core mathematics as well as a high applicability to longstanding questions within Model Theory itself. It is thus of high visibility and importance to the community.

Keywords: model theory,classification of first order structures,ampleness,tits buildings
Collaboration to develop a business plan for the Centre of Agriculture and Forestry (SMARTAgriFor)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Framework Partnership Agreement
Countries involved: Netherlands,Portugal,Portugal,Portugal,Portugal,Portugal,Portugal,Portugal
Call: Teaming (H2020-WIDESPREAD-2014-1, 2014)
Start date: 2015-04-28
End date: 2020-04-27
Duration (months): 60.0
Total project cost (EUR): 0.0
EU funding (EUR): 0.0
Participants: 13
Project status: CLOSED

The Portuguese national funding agency for Science and Technology - Fundação para a Ciência e a Tecnologia - proposes an investment (>45 million Euros) whose ultimate objective is to develop a new centre of excellence on Smart Agriculture and Forestry (SMARTAgriFor) by teaming with the Wageningen University and Research Centre in a long-term sustainable partnership. This centre is to become an international reference in the field, with the critical mass of competence to engage Portugal strategically in a path of innovative growth and also for global impact. Due to the strategic importance and leverage value envisaged for SMARTAgriFor, there is already strong support from important stakeholders including regional development authorities ensuring access to European structural funds. Further, 10 universities and 1 public research institute – representing the top performing organizations in the selected scientific domain in Portugal - will support FCT by helping develop SMARTAgriFor’s business plan in collaboration with WUR. This plan will demonstrate the centre’s potential value as a radical new approach to the topics in question. Through dynamic interaction with stakeholders, strategic partnerships will be established, funding secured, and commitments formalised to transfer infrastructure/ staff in exchange for a share in its ownership, ensuring its sustainability and financial autonomy in the long run. Clear choices have been made regarding SMARTAgriFor’s scientific focus and innovation strategy. Topics have been selected for maximum positive societal, economic and scientific impact, leveraging strategic advantage from the centre’s location in Portugal. International benchmarking will identify the optimum approach for SMARTAgriFor. Further, innovative management practices will ensure feasible implementation. Further its innovative and impact focused RTD management will allow it to connect effectively at national and international level for the application of results.

Keywords: agriculture,forestry,centre of excellence
Safe Unmanned Robotic Ensembles (SURE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Netherlands
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-09-15
End date: 2018-09-14
Duration (months): 24.0
Total project cost (EUR): 177598.8
EU funding (EUR): 177598.8
Participants: 1
Project status: CLOSED

Safe Unmanned Robotic Ensembles (SURE) Self-driving personal cars that coordinate themselves to eliminate road accidents while doubling the capacity of highways; swarms of autonomous flying machines that quickly map and explore critical areas during emergency response; fleets of service robots that inspect, clean or repair large infrastructures or vessels in a fraction of the time needed to do this manually. These are just a few examples of so called robotic ensembles, and that have the potential of revolutionizing our life in a short time span. But a key factor that can prevent them to deliver their expected benefit, is un-safety. What if such complex collective systems may be made unusable, or even dangerous, by failures or misbehaviours of a few, or even a single of their members? Threats may come from simple and inevitable physical damage occurring to individual units, or may even be the result of the deliberate action of compromised ones, due to malicious cyber-attacks directed at disrupting the service provided by the ensemble. Eradicating such scenarios is precisely the objective of the present proposal, that by directing the fellow research effort to the conception and analysis of an innovative multi-scale, adaptive and distributed diagnosis approach, will actively contribute to the creation of Safe Unmanned Robotic Ensembles (SURE). Delft University of Technology (TUD), combining top-level expertise in modelling and control of vehicular traffic flows, in distributed robotic applications, and in the conduction of robotic test-beds at its world-class experimental facilities, is a unique institution. The one where the researcher will be able to prove the effectiveness of the proposed safety techniques by operating a laboratory scale robotic test-bed. This will pave the way, within the Dutch Automated Vehicle Initiative, for trials on actual cooperative self-driving cars, a motivating example that is projected to be worth 71 billions of Euros in 2030.

Keywords: fault diagnosis,autonomous vehicles,robotic swarms,large scale systems,distributed systems,traffic networks
COLUMBUS - Monitoring, Managing and Transferring Marine and Maritime Knowledge for Sustainable Blue Growth (COLUMBUS)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: Coordination and support actions
Countries involved: Ireland,Spain,Germany,Spain,Ireland,Spain,Germany,Belgium,Belgium,Norway,Romania,Greece,France,France,Denmark,Portugal,Denmark,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call: Monitoring, dissemination and uptake of marine and maritime research (H2020-BG-2014-1, 2014)
Start date: 2015-03-01
End date: 2018-02-28
Duration (months): 36.0
Total project cost (EUR): 3997488.0
EU funding (EUR): 3997488.0
Participants: 28
Project status: CLOSED

We are standing at the dawn of a century that will be largely affected by how we as a society are able to manage our oceans and their resources. Marine and Maritime Research has a critical role to play in developing our understanding of the seas and advance technology so that we can develop their economic potential in a sustainable manner. The COLUMBUS project intends to capitalise on the EC’s significant research by ensuring accessibility and uptake of research Knowledge Outputs by end-users (policy, industry, science and wider society). COLUMBUS will ensure measurable value creation from research investments contributing to sustainable Blue Growth within the timeframe of the project. Adopting proven methodologies and building on significant past work, COLUMBUS will first identify end-user needs and priorities. It will then set about identifying and collecting “Knowledge Outputs” from past and current EC projects. Rigorous analysis will take place to identify specific applications and end-users. Transfer will be achieved and measured through tailor-made knowledge transfer. All knowledge collected will be made accessible the pre-existing Marine Knowledge Gate. To achieve the above, COLUMBUS has brought together a multi-disciplinary, multi-stakeholder team representing all aspects of the research value chain from funding agencies to end-users. Key strategic initiatives and networks further strengthen and provide a strong vehicle for project legacy. A network of 9 Competence Nodes, each with a “Knowledge Fellow” and support team across Europe will provide the necessary critical mass (470pm of effort) to ensure full thematic and spatial coverage. COLUMBUS will also carry out strategic actions to enhance the visibility and impact of research to stakeholders and European Citizen’s. Furthermore working with funding agencies and stakeholders, COLUMBUS will examine the feasibility of improved systems and processes to ensure measurable value creation from research.

Keywords: knowledge transfer,dissemination,monitoring,blue growth,innovation,msfd,knowledge exchange,knowledge brokerage,sustainability,marine,maritime,value creation
Clinical validation of a BIOmarker panel For OSTEoarthritis diagnosis: BIOFOSTE (BIOFOSTE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Italy,Italy
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2015, 2015)
Start date: 2016-04-01
End date: 2016-09-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 2
Project status: CLOSED

OSTEoarthritis (OA) is the most common degenerative joint disease in the middle-age and elderly population, that leads to disability in 40% of the adults over 70 years. The clinical manifestations of OA are pain and functional disability that can limit the normal activities of daily life and lead to depression and isolation. OA assessment is mainly carried out using radiography, which is the gold standard for diagnostic purposes. However this approach has poor sensitivity and diagnosis is obtained only when the articular cartilage has degraded significantly. Based on the extremely high economic burden, quantified in tens of billions of euro in the world, which will tend to increase in the future years, there is a need to validate OA biomarkers. In fact, although several proteins and miRNAs have been described as being altered and correlated with OA progression, there are no currently available BIOmarkers for OA diagnosis. This project concerns the development and clinical validation of a combined panel composed of proteins and miRNAs, which have been found altered in OA patients, combined with a new marker identified by IRTAL and a patented secondary chemiluminescence ELISA enhancer developed by CYANAGEN to ensure a high sensitivity for an early OA diagnosis. Our final goal is to validate and commercialize an IVD kit that may help the clinicians make an early diagnosis or predict the outcome/prognosis of OA patients, to improve the patients' quality of daily life while decreasing the related economic losses due to unproductivity, absenteeism, disability and also in terms of surgical procedures and hospitalization resources for the Health care systems. This project will allow involved SMEs to enter in the IVD market seizing the related business opportunity. In Phase 1 of the project we will select the optimal biomarkers, determine the market and clinical utility of the diagnostic test

Keywords: osteoarthritis,elisa ivd kit
IMPROVING HEMATOPOIETIC STEM CELL- BASED GENE THERAPY OUTCOME BY MODULATING CXCR4 EXPRESSION (CXCR4THERAPY)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-06-01
End date: 2020-05-31
Duration (months): 24.0
Total project cost (EUR): 173076.0
EU funding (EUR): 173076.0
Participants: 1
Project status: CLOSED

β-thalassemias and sickle cell disease (SCD) are caused by mutations in the β-globin gene (HBB) that result in the defective synthesis (β-thalassemias) or the production of an abnormal variant (SCD) of hemoglobin. Currently, the only curative option is allogeneic transplantation of hematopoietic stem cells (HSCs), but it is severely limited by conditioning toxicity and the restricted availability of compatible donors. Alternative strategies, based on lentiviral vector (LV)-mediated introduction of a functional copy of the HBB gene followed by autologous transplantation, are currently explored. Despite the fact that clinical data are promising, achieving a broad therapeutic benefit still remains a major hurdle because of inefficient gene correction and competition of the endogenous affected HSCs. In this proposal, I intend to confer an in vivo competitive advantage to transduced HSCs in terms of homing and engraftment efficiencies by modulating the expression levels of the chemokine receptor CXCR4 through two different approaches. On one hand, as increased CXCR4 levels enhance bone marrow (BM) homing, I will develop an innovative LV-based strategy to transiently deliver CXCR4 into HSCs to improve their migration to the BM. On the other hand, as CXCR4 haploinsufficiency enhances proliferation of homed HSCs, I will develop LVs down-regulating CXCR4 expression to endow corrected HSCs with an increased BM repopulating capacity. Thanks to these strategies, corrected HSCs will be able to out-compete non-corrected as well as endogenous affected HSCs, thus attaining therapeutic levels of engraftment even with a reduced number of corrected HSCs. In addition, this will contribute to use a milder conditioning regimen, normally required to eliminate endogenous affected HSCs, and thus reduce its toxicity, which preclude this treatment for patients with high disease burden. Noteworthy, this approach can potentially benefit many diseases amenable to HSC gene therapy.

Keywords: cxcr4,ex vivo hsc correction,gene therapy,multi functional lv particles,engraftment
Foresight: Autonomous machine monitoring and prognostics system for the Oil and Gas and Maritime sectors (Foresight)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Norway
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-04-01
End date: 2019-09-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Maintenance processes applied on vessels and offshore platforms are obsolete. The technologies commonly applied to monitor machinery generate Gigabytes of technical data, requiring an expert to process it. Data cannot be handled by real-time monitoring services onshore, as the data connections available offshore are not designed for such flows. As a result, only 2% of the Mobile Drilling Units (MODUs) fleet in operation nowadays implement a real-time machinery monitoring, while the other 98% apply the out-dated Time-Based Maintenance (TBM) model. TBM increases lifecycle costs due to unexpected downtimes, higher labour costs and waste of parts in working condition. MODUs and platforms are bearing today unnecessary and excessive costs due to inefficient maintenance, even human injuries or environmental catastrophes are more likely to happen due to unmaintained machinery. Our technology provides to vessels’ and platforms’ crews the possibility to monitor machinery health in real-time, allowing them to forecast and undertake the most appropriate actions. Foresight’s hardware is composed mainly by vibration monitoring equipment, that grant an easy installation onto any type of machinery. Foresight’s sensors continuously monitor the machinery, collect data, process them to reduce the size of the data packets and send them to the software on the cloud. Foresight Machine Learning (ML) module holistically processes the data gathered by sensors, synthesizing them into a comprehensive Health Index. It outperforms competitors in speed and reliability and is able to autonomously adapt and tailor its calculations on each machinery nominal behaviour. Foresight relieves vessels and platforms maintenance costs by: (1) lowering the number of sensors needed; (2) reducing data communication needs; (3) removing the need for a technical expert onboard (4) minimising unexpected downtimes; (5) avoiding replacement of sound parts.

Keywords: condition based maintenance,time based maintenance,vibration monitoring equipment,maritime assets,real time machinery health status,alignment with production work plan,unplanned downtime
UnRaveling the molEcular baSis Promoting Candidatus BrocadIa as the doMinant anaMOX genus in wastewater treatment plants (RESPIMMOX)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-03-01
End date: 2023-02-28
Duration (months): 24.0
Total project cost (EUR): 162806.4
EU funding (EUR): 162806.4
Participants: 1
Project status: CLOSED

The finding of anammox bacteria brought up the possibility of achieving energy-self-sufficient wastewater treatment plants for nitrogen removal, but their widespread technological application is still under research. The lack of pure cultures, standard cultivation methods and comprehensive genetic data make the molecular research on anammox bacteria challenging, and thus, there is a critical absence of molecular studies to understand how these bacteria make a living. One of the current challenges of anammox bacteria research is to understand niche differentiation, meaning how and why different anammox species find their unique ecological space. RESPIMMOX project aims to understand the biomolecular characteristics of anammox Ca. Brocadia that trigger their niche differentiation as the main anammox genus present in wastewater treatment plants, to improve the efficiency and stability of bioreactors. We will obtain biochemical evidence of the membrane-bound protein complexes involved in the electron transport chain of Brocadia-species, and investigate the soluble yet-unidentified enzymes responsible of the nitrite reduction. We will follow a complexome profiling approach combined with enzymatic activity assays, as commonly performed with Dehalococcoides mccartyi in the host laboratory. RESPIMMOX project will be accomplished through three specific objectives: i) achievement of an anammox Brocadia-enriched culture with high cell concentrations; ii) training of the researcher in biochemical methods to characterize respiratory complexes using the respiration with halogenated aromatic compounds as an example; and iii) identification and characterization of the protein complexes involved in the anammox Ca. Brocadia energy metabolism. The results from this proposal will entail a step forward for the understanding of anammox niche differentiation, specifically of the dominance of Ca. Brocadia in bioreactors, and will contribute to unravel the puzzle that anammox bacteria pose.

Keywords: anammox bacteria,anammox ecological niches,biochemistry of anammox bacteria,respiration of anammox bacteria,nitrite reductases,anammoxosome membrane bound proteins